Alemtuzumab in Sézary syndrome: efficient but not innocent

Eur J Dermatol. Nov-Dec 2007;17(6):525-9. doi: 10.1684/ejd.2007.0269. Epub 2007 Oct 19.

Abstract

Mycosis fungoides is the most common form of cutaneous T-cell lymphomas. The related Sézary syndrome is a more aggressive form in which the skin is diffusely affected and the peripheral blood is involved. Although easily managed during its early phases, late-stage mycosis fungoides/Sézary syndrome is usually difficult to treat and becomes refractory to chemotherapy. Recently, promising case-based results have been obtained with alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that binds to CD52 cell surface antigens, in the treatment of advanced stage mycosis fungoides/Sézary syndrome. We report a case of Sézary syndrome treated successfully with alemtuzumab but who died of treatment-related infection.

Publication types

  • Case Reports

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / adverse effects*
  • Antibodies, Neoplasm / therapeutic use
  • Antigens, CD
  • Antigens, Neoplasm
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • CD52 Antigen
  • Cytomegalovirus / genetics
  • Cytomegalovirus / isolation & purification
  • Cytomegalovirus Infections / chemically induced*
  • DNA, Viral / analysis
  • Fatal Outcome
  • Glycoproteins / antagonists & inhibitors
  • Humans
  • Lymphopenia / chemically induced*
  • Male
  • Middle Aged
  • Opportunistic Infections / chemically induced*
  • Sezary Syndrome / drug therapy*
  • Sezary Syndrome / pathology
  • Skin / pathology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antigens, CD
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • CD52 Antigen
  • CD52 protein, human
  • DNA, Viral
  • Glycoproteins
  • Alemtuzumab